185 research outputs found
CAPD Is Classified in ICD-10 as H93.25 and Hearing Evaluation-Not Screening-Should Be Implemented in Children With Verified Communication and/or Listening Deficits.
No full textPURPOSE: The article "It Is Time to Rethink Central Auditory Processing Disorder Protocols for School-Aged Children" (DeBonis, 2015) appeared in the American Journal of Audiology as a tutorial. The author used the argument made by Cowan, Rosen, and Moore (2009), referring to central auditory processing disorder (CAPD), that "such impairments have not been shown to uniquely contribute to a clearly defined condition that would warrant its inclusion in any of the major disease classification systems" (emphasis added; p. 129). However, CAPD is included in the U.S. version of the International Statistical Classification of Diseases and Related Health Problems-10th Revision (ICD-10) under the code H93.25; this was not mentioned in the article by DeBonis. We would like to point out some additional omissions of this tutorial that may bias its conclusions
"Aspiring to the condition of music": the experience of song in James Joyce's Ulysses
No full textBoston University. University Professors Program Senior theses.PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at [email protected]. Thank you.2999-01-0
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
No full textBackground: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, p = 0.006 and HR 1.75, p = 0.004, respectively) and high ALRI (HR 2.13, p = 0.001 and HR 1.76, p = 0.02, respectively), but no difference was detected according to CII value. The multivariate analysis confirmed both SII and ALRI as independent prognostic factors for PFS (HR 1.64 and 2.82, respectively) and OS (HR 1.65 and 2.12, respectively). Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
No full textBevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results of our previous analysis on patients enrolled in a randomized prospective phase III multicenter study (ITACa study) showed a predictive value of Vascular Endothelial Growth Factor (VEGF) polymorphism (VEGF + 936), a 27-nucleotide variable number tandem repeat (VNTR) of the endothelial nitric oxide synthase (eNOS) gene and eNOS + 894 polymorphism. mCRC patients, treated with Bev plus chemotherapy, were included in this prospective validation trial. eNOS + 894G > T was analyzed by Real time PCR, while the eNOS VNTR and VEGF + 936C > T were determined by standard PCR and direct sequencing analysis. These polymorphisms were assessed in relation to progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). These three polymorphisms were not predictive of PFS (p 0.91, 0.59 and 0.09, respectively), and OS (p 0.95, 0.32 and 0.46, respectively). Moreover, the haplotype analyses did not confirm what was found in our previous study; patients bearing a specific haplotype of eNOS had not significantly improved outcomes. This prospective study failed to validate the predictive impact of eNOS and VEGF polymorphisms for response to Bev plus first-line chemotherapy in mCRC patients
CIT Groups of Finite Morley Rank (I)
No full textAbstractThis is the first of two papers whose goal is the proof of the following result: THEOREM. Let G he an infinite omega-stable group of finite rank. Assume G has involutions and that the centralizer of any ivolution is a 2-group. Then one of the following holds: (1) G has a normal, nontrivial 2-subgroup. (2) G ≃ H[formula]S where H is a definable, abelian 2′-subgroup and S is a finite Sylow 2-subgroup of G with a unique involution that acts on H hy inversion. (3) G ≃ SL2(K) for some algebraically closed field K of characteristic 2. In this paper, we show that if Case 1 fails and if the Sylow 2-subgroups are finite, then we are in the second case. We also show that when G has infinite disjoint Sylow 2-subgroups, then we are in Case 3
First prospective data on breast cancer patients from the multicentre italian bone metastasis database
No full textBone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-related events (SREs) that reduce quality of life. They have also led to increased social and healthcare costs. At present, data available on BM are insufficient. This was a multicentre prospective observational study of patients with BM from breast cancer (BC) with at least 6 months’ follow-up. Information on patients at the first diagnosis of BM, including demographics and characteristics of the primary tumor and BM. Data were periodically updated by participating centres and reviewed by the coordinator centre. From October 2014 to July 2019, 618 patients with BM from solid tumors were enrolled and 220 were eligible for the present study. Median age was 62 years (range 26–86). Median follow-up was 34 months (range 6–149). At the time of enrolment, 109 (50%) had only BM (BOM) and 109 (50%) had concomitant visceral lesions and BM (BVM). Median time-to-first BM was 47 months (range 0–312) in BOM and 78.6 months in BVM patients. Disease-free interval differed on the basis of BC molecular subtype and stage. Ninety-eight BM patients had at least on SRE. Zoledronate was used in 69.1% of cases and denosumab in 28.3%. First-line treatment was hormone-based (50.7%), chemotherapy-based (38.7%) or chemotherapy- + hormone therapy-based (9.7%). Median progression-free and overall survival were 15.1 months (95% CI 12.6–18.4) and 66.8 months (95% CI 52.1–79.2), respectively. Our prospective study could substantially help to better understand the natural history of BM from BC
What are factors that explain why Black, Indigenous, and People of Color (BIPOC) or LGBTQIA2S+ individuals experience homelessness in the United States?
No full textResearch on homelessness in the United States focuses largely on personal factors, which does not allow for holistically understanding systemic factors that contribute to homelessness among BIPOC or LGBTQIA2S+ individuals. The purpose of this scoping literature review is to address the gap in literature and explore why BIPOC or LGBTQIA2S+ individuals experience homelessness in the United States. This present study uses thematic analysis to identify factors that contribute to BIPOC or LGBTQIA2S+ homelessness across 19 peer reviewed articles. Eight themes that cause homelessness emerged, such as family violence, racism, and homophobia. This research contributes to the literature on homelessness by expanding knowledge of systemic issues and social injustices minoritized individuals face that propel them into homelessness. The author concludes by discussing implications for future policies and anti-racist scholarship
Policy Analysis of the Paycheck Protection Program
No full textDuring the pandemic-induced recession, the Paycheck Protection Program (PPP) offered economic aid to small businesses to maintain their workforce and operations. This graduate project will conduct a policy analysis to examine the PPP's design, implementation, and impact on small businesses. The goal is to understand why the policy resulted in loan disparities between businesses with fewer than ten employees and larger businesses. This policy analysis uses data and information from sources available to the public and found in libraries. This policy analysis also uses a social policy framework developed by David G. Gil (1970) that incorporates a social justice lens. Due to the quick implementation of the PPP, numerous revisions were needed to increase access for smaller businesses. By the end of the program in June 2021, smaller businesses still could not attain adequate aid compared to larger businesses. Based on the results of this policy analysis, the PPP could have benefited from improved planning and coordination with lenders and businesses to enhance its effectiveness. Findings from this graduate project may offer valuable insights for policymakers regarding the effects of the PPP and suggestions for enhancing future legislation during recessions to better support the largest sector of small businesses
GALÆXI Validation: Taylor-Green Vortex
No full text
This Dataset contains the test case definition and reference data for the Taylor-Green Vortex (TGV) test case which builds the validation test case in the GALÆXI Paper (Section 5).
Incompressible TGV (Ma=0.1) according to (Link):
J. DeBonis, Solutions of the Taylor–Green vortex problem using high-
resolution explicit finite difference methods, in: 51st AIAA Aerospace
Sciences Meeting, 2013, p. 382
Compressible TGV (Ma=1.25) according to (Link):
J.-B. Chapelier, D. J. Lusher, W. Van Noordt, C. Wenzel, T. Gibis,
P. Mossier, A. D. Beck, G. Lodato, C. Brehm, M. Ruggeri, C. Scalo,
N. Sandham, Comparison of high-order numerical methodologies for
the simulation of the supersonic taylor-green vortex flow, Physics of Fluids 2024; 36 (5): 055146.
Executable of FLEXI/GALÆXI can be built using the
build.py script:
python3 build.py ./build-folder ./userblock.txt
Note: Please ensure that all necessary dependencies of GALÆXI/FLEXI are available (including CUDA) and a Python3 environment is installed on the system
For all? Analyzing the Medicare for All Act of 2019 with a critical race theory framework
No full textPurpose: Assess the Medicare for All Act of 2019. Research question: How can the Medicare for All Act of 2019 be improved by amendments and supplementary policy proposals informed by a Critical Race Theory framework of analysis? Methods: A policy analysis framework derived from Critical Race Theory is employed; the positionality of the author is also considered as the theory asserts it affects the lens of the analyst. Results: The Act will improve affordability of medical care for consumers, but social justice concerns within the Act as it is currently written should be addressed. Conclusion: Implications of the results are discussed. Suggestions for amending the act, supplementary policy proposals, as well as for future study are made
- …
